Abstract：Objective To discuss the necessity and importance of antithrombotic therapy after transjugular intrahepatic portosystemic shunt(TIPS).Methods The literatures related to TIPS treatment and postoperative from January 1994 to June 2014 were searched in Pubmed and CNKI database by using "transjugular intrahepatic portosystemic shunt", “门脉高压” as key words. The reasons for thrombosis, significance and strategies of antithrombotic therapy after TIPS were analyzed.Results Shunt thrombosis after TIPS affected the efficacy of TIPS. Antithrombotic therapy can improve stent patency rates. It plays a key role to ensure TIPS efficacy.Conclusions Antithrombotic therapy can reduce shunt thrombosis after TIPS,which is extremely important in maintaining shunt patency.
李洪翠,李肖. 经颈静脉肝内门体分流术术后抗血栓治疗的研究进展[J]. 中华解剖与临床杂志, 2016, 21(1): 82-84.
Li Hongcui, Li Xiao. Research progress of antithrombotic therapy after transjugular intrahepatic portosystemic shunt. Chinese Journal of Anatomy and Clinics, 2016, 21(1): 82-84.
Heinzow HS, Lenz P, Kehler M, et al. Clinical outcome and predictors of survival after TIPS insertion in patients with liver cirrhosis[J]. World J of Gastroenterol, 2012, 18(37): 5211-5218. DOI:10.3748/wjg.v18.i37.5211
[2]
Pomier-Layrargues G, Bouchard L, Lafortune M, et al. The transjugular intrahepatic portosystemic shunt in the treatment of portal hypertension: current status[J]. Int J Hepatol, 2012, 2012: 167868. DOI:10.1155/2012/167868
[3]
Boyer TD, Haskal ZJ, American Association for the Study of Liver Diseases. The role of transjugular intrahepatic portosystemic shunt(TIPS) in the management of portal hypertension: update 2009[J]. Hepatology, 2010, 51(1): 306. DOI:10.1002/hep.23383
[4]
García-Pagán JC, Caca K, Bureau C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding[J]. N Engl J Med, 2010, 362(25): 2370-2379. DOI:10.1056/NEJMoa0910102
[5]
Qi XS, Bai M, Yang ZP, et al. Selection of a TIPS stent for management of portal hypertension in liver cirrhosis: an evidence-based review[J]. Word J Gastroenterol, 2014, 20(21):6470-6480. DOI:10.3748/wjg.v20.i21.6470
[6]
Jalan R, Hayes PC, Redhead DN. Shunt insufficiency after TIPSS[J]. Cardiovasc Intervent Radiol, 1998, 21(3): 187-188. DOI:10.1007/s002709900242
Clark W, Golkar F, Luberice K, et al. Uncovering the truth about covered stents: is there a difference between covered versus uncovered stents with transjugular intrahepatic portosystemic shunts?[J]. Am J Surg, 2011, 202(5): 561-564. DOI:10.1016/j.amjsurg.2011.06.021
[10]
Theilmann L, Sauer P. Transjugular intrahepatic portosystemischer stent-shunt(TIPS). Indications and postoperative management[J]. Radiologe, 1994, 34(4): 164-167
[11]
Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension[J]. Hepatology, 2005, 41(2): 386-400. DOI:10.1002/hep.20559
[12]
Rssle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update[J]. Gut, 2010, 59(7): 988-1000. DOI:10.1136/gut.2009.193227
[13]
Rssle M. TIPS: 25 years later.[J]. J Hepatol, 2013,59(5):1081-1093. DOI:10.1016/j.jhep.2013.06.014
[14]
Han G, Qi X, He C, et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis[J]. J Hepatol, 2011, 54(1): 78-88. DOI:10.1016/j.jhep.2010.06.029
[15]
Fanelli F, Angeloni S, Salvatori FM, et al. Transjugular intrahepatic portosystemic shunt with expanded-polytetrafuoroethylene-covered stents in non-cirrhotic patients with portal cavernoma[J]. Dig Liver Dis, 2011, 43(1): 78-84. DOI:10.1016/j.dld.2010.06.001
[16]
Sauer P, Theilmann L, Herrmann S, et al. Phenprocoumon for prevention of shunt occlusion after transjugular intrahepatic portosystemic stent shunt: a randomized trial[J]. Hepatology,1996, 24(6):1433-1436
ter Borg PC, Hollemans M, van Buuren HR, et al. Transjugular intrahepatic portosystemic shunts: long-term patency and clinical results in a patient cohort observed for 3-9 years[J]. Radiology, 2004, 231(2): 537-545. DOI:10.1148/radiol.2312021797
[19]
Theilmann L, Sauer P, Roeren T, et al. Acetylsalicylic acid in the prevention of early stenosis and occlusion of transjugular intrahepatic portal-systemic stent shunts: a controlled study[J]. Hepatology, 1994, 20(3): 592-597
Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)[J]. Chest, 2008, 133(6 Suppl): 454S-545S. DOI:10.1378/chest.08-0658
[22]
Gallus AS, Baker RI, Chong BH, et al. Consensus guidelines for warfarin therapy-Recommendations from the Australasian Society of Thrombosis and Haemostasis[J]. Med J Aust, 2000, 172(12): 600-605
[23]
Qin JP, Jiang MD, Tang W, et al. Clinical effects and complications of TIPS for portal hypertension due to cirrhosis: a single center[J]. World J Gastroenterol, 2013, 19(44): 8085-8092. DOI:10.3748/wjg.v19.i44.8085
[24]
Eesa M, Clark T. Transjugular intrahepatic portosystemic shunt: state of the art[J]. Semin Roentgenol, 2011, 46(2): 125-132. DOI:10.1053/j.ro.2010.08.006
[25]
Kinjo N, Kawanaka H, Akahoshi T, et al. Portal vein thrombosis in liver cirrhosis[J]. World J Hepatol, 2014, 6(2): 64-71. DOI:10.4254/wjh.v6.i2.64
[26]
Senzolo M, Sartori TM , Rossetto V, et al. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis[J]. Liver Int, 2012, 32(6): 919-927. DOI:10.1111/j.1478-3231.2012.02785.x.
2016, Vol. 21 
